Dr. Peter A. Fotinakes has made it his life’s commitment to treat sleep apnea, which is his passion.
Narcolepsy is often misdiagnosed and frequently misunderstood. Most individuals experience symptoms for an average of three to five years before receiving an accurate diagnosis, although 10- to 15-year delays are not uncommon.
According to the National Institutes of Health, approximately 7.7 million American adults age 18 and older suffer symptoms of post-traumatic stress disorder (PTSD). Thankfully, emerging treatments are providing relief and recovery, even in the most severe cases.
Dr. Alina Suris has developed a cellular therapy to treat PTSD for which she has won a George Winokur Research Award.
As president and CEO of TraceLink,Inc., Shabbir Dahod leads a visionary team that helps companies meet the complex requirements of the Drug Supply Chain Security Act.
In this annual plasma-themed issue of BioSupply Trends Quarterly, we take a critical look at the current plasma market, especially issues of supply and demand.
At age 41, Eric Jordan suffered a massive ischemic stroke and lost his ability to speak.
Dr. Philip Meyers treats vascular disorders of the brain and spinal cord using minimally invasive, image-guided techniques.
As we peer into the not-too-distant future, is it possible that some of the treatments that seem so innovative today will also be looked back upon as unsophisticated?
From a bi-weekly newsletter to an award-winning quarterly magazine, BioSupply Trends Quarterly has grown to be a timely, trustworthy source for biopharmaceutical news.
Dr. Craig Kessler has been a specialist in acquired hemophilia since the late 1980s.
As CEO of FFF Enterprises, Inc., Patrick Schmidt takes pride in his company’s success in helping to secure the specialty biopharmaceuticals marketplace over the past 26 years.